PMID- 26094644
OWN - NLM
STAT- MEDLINE
DCOM- 20160606
LR  - 20150821
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 45
IP  - 9
DP  - 2015 Sep
TI  - Influence of different aetiologies on clinical course and outcome in patients 
      with dilated cardiomyopathy.
PG  - 906-17
LID - 10.1111/eci.12483 [doi]
AB  - BACKGROUND: The clinical phenotype dilated cardiomyopathy is assumed to be the 
      endstage of a multifactorial aetiopathogenetic pathophysiology which includes a 
      not satisfactorily defined group of patients with inflammatory cardiomyopathy. 
      METHODS: Within the German Competence Network Heart Failure patients with heart 
      failure due to dilated cardiomyopathy of viral/inflammatory (DCMi/v) and 
      nonviral/noninflammatory (DCM) aetiology were enrolled. After 1 year 237 patients 
      (180 male/57 female) were re-examined including complete clinical work-up. The 
      association of different clinical courses with the time from initial diagnosis of 
      heart failure (newly: </= 1 year; late: > 1 year) was investigated. RESULTS: After 
      1-year-follow-up New York Heart Association (NYHA) class (by -0.48 in newly 
      diagnosed DCM and -0.82 in newly diagnosed DCMi/v in addition to -0.24 in late 
      diagnosed DCM and -0.17 in late diagnosed DCMi/v) as well as left ventricular 
      ejection fraction (+14% in newly diagnosed DCM and DCMi/v and +6% in later 
      diagnosed DCM and DCMi/v) were significantly improved in all patients. In 
      patients with early diagnosed dilated cardiomyopathy a strong improvement of NYHA 
      class could be demonstrated. CONCLUSIONS: This study demonstrates for the first 
      time a significant interaction between duration of disease, NYHA class and left 
      ventricular ejection fraction in patients with DCM. Our results clearly 
      demonstrate that in patients with DCM an early diagnosis within 1 year after 
      occurrence of clinical signs is associated with a strong improvement in the 
      clinical course, whereas late diagnosis results in a loss of change in clinical 
      course and outcome.
CI  - (c) 2015 Stichting European Society for Clinical Investigation Journal Foundation.
FAU - Pankuweit, Sabine
AU  - Pankuweit S
AD  - Department of Internal Medicine - Cardiology, Angiology, Intensive Care and 
      Prevention, University of Marburg, Marburg, Germany.
FAU - Luers, Claus
AU  - Luers C
AD  - Department of Cardiology, Klinikum Oldenburg, University of Oldenburg, European 
      Medical School, Oldenburg, Germany.
FAU - Richter, Anette
AU  - Richter A
AD  - Department of Internal Medicine - Cardiology, Angiology, Intensive Care and 
      Prevention, University of Marburg, Marburg, Germany.
FAU - Ruppert, Volker
AU  - Ruppert V
AD  - Department of Internal Medicine - Cardiology, Angiology, Intensive Care and 
      Prevention, University of Marburg, Marburg, Germany.
FAU - Gelbrich, Gotz
AU  - Gelbrich G
AD  - Institute of Clinical Epidemiology and Biometry (ICE-B), Julius Maximilian 
      University of Wurzburg, Wurzburg, Germany.
FAU - Maisch, Bernhard
AU  - Maisch B
AD  - Herz- und Gefasszentrum Marburg (HGZ), Marburg, Germany.
CN  - German Competence Network Heart Failure
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150806
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Diuretics)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Mineralocorticoid Receptor Antagonists)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Adult
MH  - Aged
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Blood Pressure
MH  - Cardiomyopathy, Dilated/*etiology/physiopathology/therapy
MH  - Disease Progression
MH  - Diuretics/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypolipidemic Agents/therapeutic use
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Inflammation
MH  - Male
MH  - Middle Aged
MH  - Mineralocorticoid Receptor Antagonists/therapeutic use
MH  - Myocarditis/*complications/therapy/virology
MH  - Stroke Volume
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/*etiology/physiopathology/therapy
OTO - NOTNLM
OT  - Aetiology
OT  - dilated cardiomyopathy
OT  - epidemiology
OT  - heart failure
OT  - inflammation
OT  - myocarditis
EDAT- 2015/06/23 06:00
MHDA- 2016/06/09 06:00
CRDT- 2015/06/23 06:00
PHST- 2014/12/07 00:00 [received]
PHST- 2015/06/17 00:00 [accepted]
PHST- 2015/06/23 06:00 [entrez]
PHST- 2015/06/23 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - 10.1111/eci.12483 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2015 Sep;45(9):906-17. doi: 10.1111/eci.12483. Epub 2015 Aug 
      6.